Europe recommends ban on common plasma substituteBMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f3942 (Published 17 June 2013) Cite this as: BMJ 2013;346:f3942
- Jacqui Wise
The European Medicine Agency has suspended the marketing authorisation for infusion solutions containing hydroxyethyl starch, saying that their benefits no longer outweigh their risks. In the United Kingdom the Medicines Healthcare Products Regulatory Agency is reviewing the evidence and will make a decision next week.
Starch drips are mainly used to replace lost blood volume in hypovolaemia and hypovolaemic shock. They are used in critically ill patients such as those with sepsis, burn, or trauma injuries and patients …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial